MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461599 | Name: Sprodiamide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sprodiamide is a magnetic susceptibility-based MRI contrast agent.

Chemical Structure

Sprodiamide
Sprodiamide
CAS#128470-17-7 (free base)

Theoretical Analysis

MedKoo Cat#: 461599

Name: Sprodiamide

CAS#: 128470-17-7 (free base)

Chemical Formula: C16H26DyN5O8

Exact Mass: 580.1073

Molecular Weight: 578.91

Elemental Analysis: C, 33.20; H, 4.53; Dy, 28.07; N, 12.10; O, 22.11

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
128470-17-7 (free base) 140224-06-2 (hydrate)
Synonym
Sprodiamide; S-043; S 043; S043;
IUPAC/Chemical Name
dysprosium(III) 5,8-bis(carboxylatomethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oate
InChi Key
ABWHOEHSTSEVRD-UHFFFAOYSA-K
InChi Code
InChI=1S/C16H29N5O8.Dy/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3
SMILES Code
CNC(CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(NC)=O)=O.[Dy+3]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 578.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Lev MH, Kulke SF, Sorensen AG, Boxerman JL, Brady TJ, Rosen BR, Buchbinder BR, Weisskoff RM. Contrast-to-noise ratio in functional MRI of relative cerebral blood volume with sprodiamide injection. J Magn Reson Imaging. 1997 May-Jun;7(3):523-7. PubMed PMID: 9170037. 2: Lai JJ, Jamieson GC. Determination of dysprosium in monkey serum by inductively-coupled plasma atomic emission spectrometry (ICP-AES) after the administration of Sprodiamide Injection, a new contrast medium for magnetic resonance imaging. J Pharm Biomed Anal. 1993 Nov-Dec;11(11-12):1129-34. PubMed PMID: 8123724. 3: Saeed M, Martin AJ, Lee RJ, Weber O, Revel D, Saloner D, Higgins CB. MR guidance of targeted injections into border and core of scarred myocardium in pigs. Radiology. 2006 Aug;240(2):419-26. Epub 2006 Jun 26. Erratum in: Radiology. 2007 Jan;242(1):320. PubMed PMID: 16801371. 4: Saeed M, Wendland MF, Szolar D, Sakuma H, Geschwind JF, Globits S, Derugin N, Higgins CB. Quantification of the extent of area at risk with fast contrast-enhanced magnetic resonance imaging in experimental coronary artery stenosis. Am Heart J. 1996 Nov;132(5):921-32. PubMed PMID: 8892762. 5: Roberts TP, Kucharczyk J, Cox I, Moseley ME, Prayer L, Dillon W, Bleyl K, Harnish P. Sprodiamide-injection-enhanced magnetic resonance imaging of cerebral perfusion. Phase I clinical trial results. Invest Radiol. 1994 Jun;29 Suppl 2:S24-6. PubMed PMID: 7928245. 6: Van Beers BE, Goudemant JF, Oksendal A, Jamart J, Delos M, Thiran JP, Demeure R, Pringot J, Maldague B. Detection of reperfused ischemia of the rat intestine: value of magnetic resonance imaging with small-molecular-weight dysprosium and gadolinium chelates. Acad Radiol. 1997 Jan;4(1):35-42. PubMed PMID: 9040868. 7: Zhao S, Revel D, Arteaga C, Canet E, Liu S, Hadour G, Forrat R, Oksendal A. Magnetic susceptibility of Dy-DTPA-BMA to reperfused myocardial infarction in an excised dog heart model: evidence of viable myocardium. Chin Med J (Engl). 2000 Mar;113(3):260-4. PubMed PMID: 11775260. 8: Arteaga C, Revel D, Zhao S, Hadour G, Forrat R, Oksendal A, Canet E. Myocardial "low reflow" assessed by Dy-DTPA-BMA-enhanced first-pass MR imaging in a dog model. J Magn Reson Imaging. 1999 May;9(5):679-84. PubMed PMID: 10331763. 9: Saeed M, Wendland MF, Lauerma K, Sakuma H, Chew W, Derugin N, Higgins CB. First-pass contrast-enhanced inversion recovery and driven equilibrium fast GRE imaging studies: detection of acute myocardial ischemia. J Magn Reson Imaging. 1995 Sep-Oct;5(5):515-23. PubMed PMID: 8574034. 10: Dupas B, Buzelin MF, Karam G, Vasse N, Meflah K, Bach-Gansmo T. Contrast-enhanced MR imaging of experimental acute tubular necrosis. Acta Radiol. 2001 Jan;42(1):74-9. PubMed PMID: 11167336. 11: Fowler RA, Fossheim SL, Mestas JL, Ngo J, Canet-Soulas E, Lafon C. Non-invasive magnetic resonance imaging follow-up of sono-sensitive liposome tumor delivery and controlled release after high-intensity focused ultrasound. Ultrasound Med Biol. 2013 Dec;39(12):2342-50. doi: 10.1016/j.ultrasmedbio.2013.06.002. PubMed PMID: 24246245. 12: Saeed M, Li HT, Wendland MF, Knollmann F, Higgins CB. Comparison of cardiovascular response to ionic and nonionic magnetic resonance susceptibility contrast agents. Invest Radiol. 1994 Mar;29(3):319-29. PubMed PMID: 8175307. 13: Sebastiani G, Godtliebsen F, Jones RA, Haraldseth O, Muller TB, Rinck PA. Analysis of dynamic magnetic resonance images. IEEE Trans Med Imaging. 1996;15(3):268-77. PubMed PMID: 18215908. 14: Ericsson A, Bach-Gansmo T, Niklasson F, Hemmingsson A. Combination of gadolinium and dysprosium chelates as a cellular integrity marker in MR imaging. Acta Radiol. 1995 Jan;36(1):41-6. PubMed PMID: 7833167. 15: Higgins CB, Saeed M, Wendland M. Contrast enhancement for the myocardium. Magn Reson Med. 1991 Dec;22(2):347-53; discussion 364-5. PubMed PMID: 1812369. 16: Kucharczyk J, Vexler ZS, Roberts TP, Asgari HS, Mintorovitch J, Derugin N, Watson AD, Moseley ME. Echo-planar perfusion-sensitive MR imaging of acute cerebral ischemia. Radiology. 1993 Sep;188(3):711-7. PubMed PMID: 8351338. 17: de Crespigny AJ, Tsuura M, Moseley ME, Kucharczyk J. Perfusion and diffusion MR imaging of thromboembolic stroke. J Magn Reson Imaging. 1993 Sep-Oct;3(5):746-54. PubMed PMID: 8400561. 18: Moseley ME, Kucharczyk J, Mintorovitch J, Cohen Y, Kurhanewicz J, Derugin N, Asgari H, Norman D. Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am J Neuroradiol. 1990 May;11(3):423-9. PubMed PMID: 2161612. 19: Kucharczyk J, Roberts T, Moseley ME, Watson A. Contrast-enhanced perfusion-sensitive MR imaging in the diagnosis of cerebrovascular disorders. J Magn Reson Imaging. 1993 Jan-Feb;3(1):241-5. Review. PubMed PMID: 8428092. 20: Moseley ME, Vexler Z, Asgari HS, Mintorovitch J, Derugin N, Rocklage S, Kucharczyk J. Comparison of Gd- and Dy-chelates for T2 contrast-enhanced imaging. Magn Reson Med. 1991 Dec;22(2):259-64; discussion 265-7. PubMed PMID: 1812356.